Is There a Role for the Therapeutic Drug Monitoring of Colistin? An Overview
Is There a Role for the Therapeutic Drug Monitoring of Colistin? An Overview
复制标题
DOI：
10.3390/ph13030042
复制
发表时间：
2020-03-01
期刊：
影响因子：
4.6
通讯作者：
Jaimes, Diego
中科院分区：
文献类型：
--
作者：
Avila, Maria-Paula;Pacheco, Tatiana;Jaimes, Diego
粘菌素用作治疗革兰氏阴性多重耐药菌的最后一线抗生素。由于其肾毒性较高，建议通过治疗药物监测（TDM）进行剂量调整。我们的目的是评估使用粘菌素治疗革兰氏阴性菌感染的患者中 TDM 的现有证据。在本文中，我们通过电子检索文献（截至 2019 年 6 月出版，无语言限制）提供了概述，比较了粘菌素 TDM 的临床结果和测量结果。最终，血浆中粘菌素的治疗药物监测（TDM）可以预防肾毒性风险。
Colistin is used as a last-line antibiotic for the treatment of Gram-negative multiresistant bacteria. Due to its high nephrotoxicity, Therapeutic Drug Monitoring (TDM) is recommended for dose adjustment. We aimed to evaluate the available evidence of TDM in patients given colistin to treat Gram-negative infections. In this paper, we offer an overview, using an electronic search of the literature (published up to June 2019, without language restrictions) that compares the clinical outcomes and measurements of colistin TDM. Ultimately, the Therapeutic Drug Monitoring (TDM) of colistin in Plasma could prevent nephrotoxicity risk.